Introduction {#S1}
============

The use of sentient animals for research purposes is a controversial topic, which has raised public and ethical concerns and is criticized by opponents claiming that animal models often do not generate appropriate benefit with regards to their potential risks and harm and as a consequence, are often ethically not permissible. The increasing status of pets as family members and corresponding high level of veterinary care for privately owned pets further amplifies the controversy over the use of animals for research purposes.

However, animal models are still an important and, at a regulatory level, a compulsory component of translational research, which cannot yet be replaced by *in vitro* experiments. Although *in vitro* models allow for systematic, standardized analysis of various cellular, biophysical and biochemical cues in a controlled environment, without the natural variability inherent to *in vivo* animal models, they can only offer an abstract insight into the pathophysiology of diseases and disorders. Therefore, while animal models cannot yet be replaced, the number of animals used should be reduced to a minimum and experiments involving animals should be optimized with regard to their translatability and the welfare of the animals.

However, to date a reductionist approach often using immature laboratory species is commonly employed ([@B165]). Small rodent animals, specifically mouse and rat, are valuable for research into mechanisms of disease and fundamental biology, but findings from such small animal models often do not translate into human clinical applications ([@B297]; [@B213]). Shanks et al. impressively illustrated the translational challenges, showing the difference in bioavailability of pharmaceuticals between humans, primates, dogs and rodents ([@B324]). However, although awareness is increasing there is still a massive disproportion between rodent studies and large animal studies.

Therefore, the European Medicines Agency (EMA), the USA Federal Food and Drug Administration (FDA) and the International Society for Stem Cell Research (ISSCR) recommend the use of large animal models to evaluate efficacy, durability, dose response, degradation and safety of advanced therapeutic medicinal products (ATMPs)^[1](#footnote1){ref-type="fn"}^ ^,[2](#footnote2){ref-type="fn"}^. For successful and timely translation from animal models to regulatory approval and clinical application, a step-wise development using laboratory animals for screening and early development work, followed by a large animal model such as the pig, sheep or horse which offers a more realistic approach for late development and pivotal studies would be more appropriate ([@B158]).

Moreover, animals develop many naturally occurring (or spontaneous) diseases that are equivalent to human disease leading to the development of the "One Health One Medicine" concept which presumes that diseases in men and animals (mostly mammals) have similar aetiologies and pathophysiologies and require analogous therapeutic approaches. Hence, human and veterinary medicine can mutually benefit from research that applies a one health approach. Using large animal models with naturally occurring disease with a similar pathophysiology as in humans, allows study of not only new treatment strategies but also disease development and prevention at a relevant age. However, although using naturally occurring disease models best reflect disease complexity, standardization of disease grade and availability of sufficient clinical case numbers for recruitment into studies can be challenging.

In order to achieve the best output while following the three R's principle (to **r**educe, **r**efine and **r**eplace animal models) of using the smallest possible number of animals, animal models need to be optimized to the greatest possible extent ([@B215]). They require careful selection and design to ensure they are fit-for-purpose and address both optimal predictive validity, as well as ethical, animal-welfare and societal considerations. Species, anatomic, physiologic, biomechanical aspects and their clinical relevance need to be considered.

Furthermore, knowledge regarding the epidemiology and natural history of diseases in different animal species, disease similarities to humans, availability of diagnostics, treatment options, and outcome measures as well as criteria defining species specific quality of life and functional parameters is important but still scarce in the scientific community. Other important considerations in using large animal models include availability, handling and economic concerns.

To optimize scientific output and translational potential with animal welfare needs, tight cooperation between basic science, human and veterinary medicine is necessary. The veterinary academic environment offers unique expertise to make that goal attainable to the highest standards. This includes the veterinary knowledge required to make a rational decision for the choice of animal model rather than being based on in-house availability.

There are several research groups which have a track record of developing preclinical large animal models, some of which have managed to translate their research into clinical applications ([@B176], [@B175]; [@B241], [@B242]; [@B130]; [@B337]; [@B12]; [@B384]; [@B131]; [@B356]; [@B37]; [@B355]). This − by no means exhaustive − list clearly demonstrates the collective efforts of the veterinary community to provide large animal models to be used in translational projects.

However, yet it is still often argued, that translational studies using large animal models are rare because they are complex, time-consuming, technically demanding, slow, and usually not suitable for mechanistic investigations. Nevertheless, because large animals better reflect the human body conformation and pathophysiology of certain naturally occurring diseases than rodent models, these studies are essential justifying the challenges and costs. Unfortunately, the added value of the clinical relevance of large animal models is often not appreciated by reviewers of manuscripts and grant applications are assigned low scores on the basis of lack of mechanistic insights and insufficient conceptual novelty. However, for a successful translation of tissue engineering and regenerative medicine research into clinical therapies, it is critical that this misperception is corrected.

It is the authors' hope that this review, which introduces different large animal models, their naturally occurring diseases and their specificities, may stimulate biomedical researchers to look for the very best model possible for their specific research question and that it will encourage interdisciplinary cooperation to optimize the choice of disease-relevant animal models in the future. Deciding which animal model should be used in a particular study is first and foremost dependent on defining the specific question that needs to be answered. Only then can the pertinent benefits and drawbacks of individual models be considered and a decision made.

In this review, we focus on horses, sheep, dogs, cats and pigs as the most frequently used large animal models in research and do not include primates due to the ethical dimension and limited indications, which require their specific use. Using animals which are so similar to humans, raises serious ethical concerns. Therefore, the use of non-human primates is closely monitored and strictly regulated and much has been done to specifically safeguard these animals. The use of great apes has been completely prohibited. As long as non-human primates are used for medical research, the European Commission strongly advocates the "3Rs principle," now a legal obligation embedded in the EU legislation to: Replace non-human primates with viable alternatives whenever feasible, Reduce the use of non-human primates and Refine scientific procedures and the care and treatment of the animals. Even phasing-out the use of non-human primates in Europe is discussed^[3](#footnote3){ref-type="fn"}^.

Why the Choice of Animal Models Is Crucial {#S2}
==========================================

The most obvious and demonstrative reason why the choice of animal models is crucial, are gross anatomic differences between the human and different animals and even between animals of different species ([Figure 1](#F1){ref-type="fig"}). These differences imply that the same anatomic structures may have a different function and are subjected to different biomechanical strains. [Table 1](#T1){ref-type="table"} illustrates differences of different animals to emphasize the importance of correct model selection with respect to species' physiologic aspects.

![Gross anatomical differences between animals of different species (courtesy of Niklas Dresen, Institute of veterinary anatomy, University Leipzig) and the human (courtesy of Elfriede Cremer, Bernhard Cremer and Elisabeth Schieder). **(A)** Pig; **(B)** Sheep; **(C)** Dog; **(D)** Horse; **(E)** Mouse; **(F)** Human.](fbioe-08-00972-g001){#F1}

###### 

Comparison of physiologic and biomechanical parameters of different model animals.

  **Species**                                                       **Mouse (C57BL/6)**                                 **Rat**     **Rabbit**    **Canine**    **Mini-Pig**   **Sheep**      **Goat**       **Horse**      **Human**
  ----------------------------------------------------------------- --------------------------------------------------- ----------- ------------- ------------- -------------- -------------- -------------- -------------- -------------
  Body temperature (in °Celsius)                                    36.5−37.3°C                                         37.5−39.5   38.0−39.5     38.0−39       38.3−38.8      38.5−39.5      38.3−39.0      37.5−38.0      36.5−37.3
  Heartrate (beats per minute)                                      491−626                                             250−450     150−300       60−160        68−72          60−80          60−80          28−40          60−80
  Respiration rate per minute                                       272                                                 70−120      35−100        15−30         14−18          16−30          10−30          10−14          12−20
  Cartilage thickness medial femoral condyle (in mm)                0.1                                                             0.3           0,6−1.3       1.5            0.7−1.7        0.7−1.5        1.75           2.35
  Critical size cartilage defect (in mm)                                                                                1.4         3             4             6              7              7              9              10
  Subchondral bone plate thickness medial femoral condyle (in mm)                                                                   0.4−0.5                                    0.7            0.3            0.7            0.2−0.5
  Anterior cruciate ligament length (in mm)                                                                                         10.6          21.2          37.0           31.77                                        37.78
  Anterior cruciate ligament diameter (in mm)                                                                                       4.84          5.45          10.86          9.27                                         12.73
  Posterior cruciate ligament length (in mm)                                                                                        10.0          22.8          39.68          37.03                                        40.30
  Posterior cruciate ligament diameter (in mm)                                                                                      4.34          5.33          8.2            6.67                                         14.23
  Medial Meniscus length (in mm)                                                                                                    9.2           16.83         25.32          25.63                                        39.8
  Lateral meniscus length (in mm)                                                                                                   10.0          16.3          25.60          26.03                                        33.28
  Range of motion -- knee joint extension (in °)                                                                                    22            34            42             40             45                            2.5
  Range of motion -- knee joint extension (in °)                                                                                    161           160           144            146.7          145.5                         137.5
  Age of skeletal maturity (age until growths plates remain open)   3−6 months (growths plates remain open life−long)               16−39 weeks   12−24 weeks   42−52 weeks    36−48 months   36−48 months   60−72 months   18−22 years
  Weight at skeletal maturity in kg                                 20−40 g                                             0.25−0.55   3−4           1−30          20−40          40−70          40−70          450−500        60−90
  Life span in years                                                2                                                   2.5−3.5                   10−15         15             10−12          15−18          30             70−80
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Age Matters {#S2.SS1}
-----------

Age should be an important consideration in the choice of any animal model independent of the species used ([@B165]). For practical and organizational reasons animal trials are often carried out in juvenile or neonatal animals. However, differences in the healing potential and therefore the healing response between juvenile and adult animals can bias the outcome of such trials ([@B269]; [@B23]; [@B63]; [@B104]; [@B33]; [@B8]; [@B66]; [@B253]; [@B369]; [@B165]). The use of skeletally mature animals of an appropriate age ([Table 1](#T1){ref-type="table"}) to mimic adult disease and healing potential is therefore a critical consideration for optimal study design. To truly reflect human age-related disease, the animals used should be of comparable age. Ideally old animals would be used to study age-related diseases as for instance senile osteoporosis. However, the use of elderly compared to immature or young adult animals requires specific considerations, as aged animals are more difficult to procure and may suffer from comorbidities. Hence, potential animal loss due to other diseases needs to be accounted for in the study design and financial planning. Furthermore, the predisposition for age-related diseases varies between species.

Naturally Occurring and Generated Models of Genetic Disease {#S2.SS2}
-----------------------------------------------------------

Many naturally occurring genetic diseases have been identified in companion and farm animals which are often caused by a mutation in an orthologous gene and lead to a comparable clinical phenotype as observed in human patients, including the pathological alterations at the biochemical and cellular levels ([@B196]; [@B187]). Most of these animal models are associated with congenital heart disease, lysosomal storage disease, hemophilia, muscular dystrophies, neurological disorders, immunodeficiencies and dwarfism ([@B196]). Information about these naturally occurring genetic diseases in animals was compiled in a comprehensive database − Online Mendelian Inheritance in Animal − created by Prof. Frank Nicholas at The University of Sydney and Australian National Genomic Information Service^[4](#footnote4){ref-type="fn"}^.

Naturally Occurring and Generated Models of Musculoskeletal Disease {#S2.SS3}
-------------------------------------------------------------------

Osteoarthritis (OA) is a heterogeneous disease for which no single animal model perfectly recapitulates the complex etiology and clinical manifestations of the human disease ([@B2]; [@B61]; [@B209]; [@B238]). Currently available OA models are generally grouped into spontaneous, or surgically induced models. Spontaneous models include naturally occurring disease or genetically manipulated models, whereas surgically induced models employ (i) destabilization of the joint such as partial or total meniscectomy, meniscal tear, anterior cruciate ligament or posterior cruciate ligament transection, medial and/or lateral collateral ligament transection or osteotomy (ii) physical defects of the articular cartilage such as creation of articular grooves, (iii) impact trauma including transarticular impact, and intra-articular osteochondral fragmentation (iv) chemically induced lesions using intra-articular injection of monosodium iodoacetate, collagenase, carrageenan or Freund adjuvant ([@B22]; [@B209]; [@B197]; [@B238]). Spontaneous models that develop progressive and chronic disease are likely to more closely mimic idiopathic OA. However, these models take longer to develop and tend to be more variable with respect to outcome measures ([@B373]; [@B354]; [@B197]; [@B238]).

Surgical models have the advantage of repeatability and reproducibility as well as rapid onset and progression ([@B197]), but for that reason are less ideal models of spontaneous OA and are often regarded as posttraumatic (secondary) OA ([@B21]; [@B208]; [@B354]; [@B238]).

The validity of chemically induced models for OA has been questioned ([@B295]; [@B354]) due to the resulting widespread cell death and rapid joint destruction, which are not considered typical for either spontaneous or posttraumatic OA ([@B209]).

Animal models are further widely used in osteoporosis research. They include, among others, models for disuse induced osteoporosis, glucocorticoid-induced osteoporosis and postmenopausal osteoporosis. The most popular animal models of postmenopausal osteoporosis are those generated in the mouse, rat, sheep, and nonhuman primates by ovariectomy ([@B164]).

The choice of the animal models differ markedly, depending on the objectives of the study. It has to be noted that rodents for example are of limited value for investigating intra−cortical bone remodeling, because they lack true Haversian cortical bone remodeling under physiological conditions due to their small weight ([@B15]; [@B202]; [@B164]). Larger animals such as dogs are more appropriate for these studies because, similar to humans, dogs have well-developed Haversian remodeling ([@B164]).

Challenges of Translating Results From Animal Models to Human Patients -- An Example {#S2.SS4}
------------------------------------------------------------------------------------

To date, animal models of human asthma have included: Drosophila, rats, guinea pigs, cats, dogs, pigs, cattle, sheep, horses and primates, but the most widely used model is the mouse ([@B396]; [@B181]; [@B325]; [@B28]). The mouse is a useful model due to the availability of specific probes and reagents for studying allergic outcomes, such as cellular and humoral responses, and the good adaptability for genetic manipulation ([@B325]; [@B31]). Nevertheless, this model has some limitations for translational medicine mainly related to the anatomical and physiological differences with respect to man. Obviously, the lung and bronchial tree, total lung capacity (6 liter for man vs. 1 ml for mouse), and the blood-gas barrier thickness (0.62 μm vs. 0.32 μm) are much smaller than in man and the bronchial artery supplies the entire lung in man but is absent in the pleura, septa and alveoli in mice. In addition, the respiratory rate, or beats per minute (10−14 vs. 250−350), is very different in people and mice. Moreover, the mouse lacks sub-mucosal glands and has limited airway smooth muscles compared to man ([@B198]). In view of these important differences, the pre-clinical results obtained when using a mouse model for asthma should be interpreted with care. Furthermore, the mouse does not have natural inflammatory or allergic pulmonary pathologies, so airway inflammation is usually induced by exposure to ovalbumin (OVA) or other aeroallergens. In contrast to naturally occurring human asthma, which is a chronic disease characterized by persistent inflammation and remodeling due to intermittent or continuous inhalation exposure to allergens resulting in chronic eosinophilic/neutrophilic inflammation ([@B11]; [@B40]), the mouse model shows more acute (\<3 months) inflammation and no remodeling. To circumvent this problem, systemic sensitization protocols and repeated exposures to allergens have been tried but the results obtained from different routes of systemic sensitization (subcutaneous injection, intraperitoneal injection or intranasal inhalation) and different allergens (OVA, fungi, *Ascaris* antigens, house dust mite, cockroach extracts), used alone or in combination, are difficult to compare and to interpret ([@B11]). For example, in the mouse the induced inflammation profile, although dependent on the antigen, is mainly Th2, mirroring disease in only a subsection of human asthmatics who are Th2 and/or Th1/Th17 ([@B88]; [@B387]). Another criticism of the mouse model is that OVA does not induce asthma in human patients and the sensitization routes do not mimic the routes of exposure to allergens in human asthma ([@B11]). Hence, differences in the results may be due to the different types of allergens and sensitization routes.

An appropriate animal model for translational studies should mimic the pathological changes associated with human asthma and reflect the environmental factors that determine the evolution of human asthma.

Horses as Animal Models {#S3}
=======================

General Considerations {#S3.SS1}
----------------------

Horses (*equus caballus*) are a well-accepted, well-established and clinically relevant animal model particularly for musculoskeletal disease, which is of major interest in regenerative medicine.

An important aspect of clinical research is the precise demonstration of the initial injury, the disease progress, outcome and follow up. The validated applicability of advanced diagnostic methodologies in horses such as arthroscopy and MRI (together with scoring approaches) ([@B36]; [@B225]), ultrasound, radiographs, CT and scintigraphy, has made the horse a popular model for which non-terminal studies with thorough evaluation and monitoring are possible. Also, second-look arthroscopy and serial sampling are feasible. Moreover, the large size of horses allows for the creation of critical size defects or multiple defects and offers a high amount of material that can be sampled for analysis. This enables large and comprehensive studies which may not be possible in smaller animals. Together with well-established histologic scoring ([@B243]) and pain scores ([@B298]; [@B136]; [@B75]; [@B129]) or assessment of other clinical parameters for horses these methods facilitate comparability of diagnosis, follow-up and results. Controlled postoperative exercise programs and rehabilitation protocols using e.g., treadmills and horse walkers further support standardization of the results. A broad offer of modern methods to further objectify outcome measures became available including gait kinematics (e.g., lameness locators) and/or kinetics using force plate/ground reaction force analysis.

Also the lack of traceability of cells injected for cell therapies could be overcome to a certain extent by using either super paramagnetic iron oxide particle (SPIO) for MRI ([@B79],[@B80]; [@B172]; [@B26]; [@B41]) or nuclear labeled (Technetium 99M, GFP, Indium 111) cells for scintigraphic tracing ([@B338], [@B339]; [@B19]; [@B362]; [@B92]; [@B343]; [@B102]; [@B127]; [@B315]).

Some disadvantages of using the horse as a model include high costs of animal of animal purchase, maintenance/handling as well as ethical concerns and lower acceptance of the horse as an experimental animal compared to small animal studies by the lay public. In addition, some key parameters building the framework used in studies applying Omics approaches are not well enough researched in horses yet. A restrictive annotation status and availability of equine specific antibodies, molecular tools and markers are limiting factors. A major challenge when using horses is that their weight precludes non-weight-bearing investigations postoperatively. Significant limitations may arise regarding biomechanical strains, which far exceed those considered physiologic in humans and other animal models, which could render the stabilization of injured structures, transplants and/or sutures ineffective. Therefore, horses are a less amenable model for meniscus or bone repair. Nonetheless, these are major challenges in equine patients and several different attempts have been made or are envisaged to support healing of these structures by regenerative medicine approaches ([@B117]; [@B254]; [@B110]; [@B182]; [@B239]; [@B323]; [@B378]; [@B135]; [@B393]; [@B132]) which may also hold valuable preclinical results for human medicine. For example, hyperextension of the stifle joint was found to lead to pathologic levels of forces and injury in the cranial horn of the equine medial meniscus, analogous to observations in the human posterior medial horn upon hyperflexion ([@B90]).

Tendinopathy {#S3.SS2}
------------

Horses commonly suffer from naturally occurring tendon injuries (tendinopathy) and degenerative joint disease (osteoarthritis − OA) with similar pathophysiology to the human in terms of etiology and risk factors, which include over-exercise, age and genetic factors ([@B133]; [@B282]; [@B242]; [@B376]; [@B334]; [@B6]). As athletic individuals, horses incur idiopathic primary or sports related injuries to tendon and joint related tissue.

An example is the equine superficial digital flexor tendon (SDFT) which performs a similar function to the human Achilles tendon during high-speed locomotion. In both species, their respective tendons are one of the most frequently injured ([@B166]; [@B359]) with age and participation in sports as key risk factors. The SDFT supports the metacarpophalangeal (MCP) joint and functions as an energy storing elastic tissue to enable efficient locomotion. During high-speed locomotion the SDFT can experience strains of 16% as the MCP joint hyperextends. These strains are within the functional limit of the SDFT at which failure can occur ([@B304]). The Achilles tendon can experience strains of up to 8% allowing as much as 34% of the total work performed by the calf muscles to be stored in the Achilles ([@B123]).

Acute and chronic Achilles tendon pathology is estimated to be responsible for as many as 50% of all sports-related injuries in humans ([@B123]; [@B216]; [@B166]). The incidence of SDFT tendinitis in horses is reported to be as high as 8−43% ([@B89]). Injuries in both often manifest within the body of the tendon as core lesions, which heal by the formation of fibrous scar tissue. This scar tissue is biomechanically inferior with significantly reduced elasticity which leads to a high risk of re-injury ([@B335]). It is therefore essential that repair strategies are aimed at restoring function by achieving scar-free healing for which regenerative medicine holds great potential. Studies in the horse to test and improve cell and cell free therapies for tendon regeneration ([@B336]; [@B279]; [@B304]; [@B319]; [@B116]; [@B194]; [@B335]; [@B130]; [@B222]; [@B49]; [@B303]; [@B337]; [@B367]; [@B126]; [@B267]) could serve as preclinical data for human medicine.

However, due to the challenges of standardization of disease grade and availability of sufficient clinical case numbers for recruitment of horses with naturally occurring disease, a number of induced equine models have been developed to investigate both tendon and joint disease.

Several surgically induced tendon injury models have been developed to try to achieve a standard lesion size, anatomical location and the ensuing inflammatory response as well as time to treatment ([@B139]; [@B320]; [@B47]; [@B42]). While most of these are aimed at partial or full transection of the tendon, the mechanically induced model described by [@B320] mimics a typical tendon core lesion of spontaneous disease with similarities in healing characteristics ([@B42]). In contrast, collagenase induced tendon injury models which attempt to mimic core lesions ([@B385]; [@B274]; [@B257]; [@B318]; [@B72]; [@B177]; [@B381], [@B380]; [@B49]) lead to a strong inflammatory response and are difficult to standardize with respect to location, size, shape and volume due to leakage of collagenase through the injection sites and uncontrollable diffusion from the center of the tendon ([@B320]).

Cartilage Injuries and Osteoarthritis {#S3.SS3}
-------------------------------------

Another example to illustrate "what the horse can tell the human" is Osteoarthritis, a degenerative joint disease characterized by progressive loss of articular cartilage. Adult articular cartilage has limited capacity for repair and regeneration ([@B179]). Any disruption of the superficial zone, or injury to the chondrocytes that maintain the cartilage matrix and zonal architecture, affects the load-distribution of the viscoelastic hyaline cartilage and may ultimately culminate in degenerative joint disease ([@B308]). OA of the knee and hip joints is one of the most commonly diagnosed diseases in human general practice with 52 million people (=22.7% of adults older than 18 years) in the United States and an estimated 30 -- 40 million Europeans suffering from arthritis of one or more joints ([@B54]; [@B170]). With age and obesity as key risk factors the prevalence of OA is expected to double by the year 2020 ([@B170]). As currently no proven disease-modifying therapy capable of restoring damaged articular cartilage and function of the joint is available, there is an increasing demand for novel, safe and effective treatments, which regenerative medical research could offer. In equids as for human patients, there is an unmet need for early diagnosis and effective treatments that allow return to full performance ([@B238]). In horses OA constitutes the main cause of chronic lameness with an incidence of chronic degenerative joint disease in elderly horses of up to 83.5%. Interestingly, not only is the pathophysiology of equine OA similar to the human but also the thickness of the knee cartilage is similar to the human ([@B120]; [@B219]). These similarities support the horse as relevant model for studies on naturally occurring OA.

A number of surgically induced equine models of articular cartilage degeneration and healing have been developed which were reviewed by [@B241]. As in humans, the major aims of OA research are to achieve resurfacing of the damaged cartilage with biomechanically resilience and acceptable pain control. However, for any studies on cartilage repair it is important that the duration should be at least 8 to 12 months, as failure at long-term follow-up is a common outcome in human and equine clinical trials even if short-term results look promising in animal models ([@B241]).

Asthma {#S3.SS4}
------

Horses, analogous to humans, commonly suffer from asthma. Asthma is a chronic inflammatory disease characterized by airway hyper-responsiveness and airway remodeling due to increased mucus production, epithelial fibrosis, hypertrophy and hyperplasia of airways smooth muscles, and gland enlargement ([@B327]). This remodeling can induce irreversible obstruction of airways and may be a consequence of chronic tissue inflammation and altered repair processes. Since function and structure are closely related, the hypothesis is that remodeling leads to loss of airway and lung function ([@B40]).

Around 300 million people worldwide (both adults and children) suffer from asthma and hence the societal impact is high^[5](#footnote5){ref-type="fn"}^. The standard therapy is based on corticosteroid administration to reduce airway obstruction thus improving quality of life. However, about 20% of people are corticosteroid resistant and do not respond to therapy ([@B280]). Corticosteroid therapy is reparative and not regenerative and does not counteract remodeling. Better therapies may be derived from a regenerative approach to asthma-induced pathology.

The gold standard species for studies into human asthma would be human patients, but such studies are ethically impossible, because of the large number of patients requiring repeated biopsies to understand the causes of remodeling. Therefore, although requiring ethical authorizations, animal models are essential to advance understanding of the disease.

Severe equine asthma (SEA), which occurs spontaneously in horses ([@B152]; [@B386]), shares many features with human asthma. The horse has potential to be a good animal model with similar lung anatomy to man. SEA shares many features with human asthma: lower airway inflammation, completely reversible airflow obstruction, bronchial hyperresponsiveness, increased respiratory efforts at rest, coughing and exercise intolerance ([@B39]; [@B69]). This condition is spontaneously triggered by exposure to environmental antigens present in horse housing, similar to exposure in man and it can become incurable like chronic asthma in people. Up to 10--15% of adult horses suffer from SEA ([@B155]) with a Th-2 predominant cytokine profile (increase of IL-4), as described in human asthma ([@B200]; [@B184]), and decrease of Th-1 profile (decrease of interferon-γ). The predominant cell type in bronchoalveolar lavage fluid (BALF) found in horses may be different to humans depending on the severity of asthma: horses with severe and late-onset asthma have neutrophilic inflammation ([@B280]) as demonstrated in some people ([@B68]), while increased eosinophils are frequently detected in milder forms of equine asthma ([@B69]). As in people with neutrophilic asthma, horses with SEA can show an increase in Th-17 expression ([@B78]; [@B68]).

In a good animal model, homology of genes regulating immune function is essential and the horse shares higher homology with man for *IL2, IL23*, and *IL17*, compared to the mouse ([@B361]; [@B198]). However, the most interesting aspect of the horse as a model to study asthma is airway remodeling, although this is less marked and involves the bronchial tree more peripherally than in man ([@B40]). The remodeling can be completely reversed by appropriate corticosteroid treatment in both human patients and horses ([@B40]) and sequential biopsies can be collected from the same standing sedated horse without the imperative to sacrifice the animal as compared to the mouse ([@B201]).

Additional Considerations Regarding Horses {#S3.SS5}
------------------------------------------

In horses' wounds on the distal limbs show delayed healing compared to wounds located on the upper body.

Reasons for this are not fully understood. However, differences in the rate of epithelization and wound contraction, inefficient inflammatory response (resulting in chronic inflammation and hence impaired formation of healthy granulation tissue), imbalance in collagen homeostasis, profibrotic environment, tissue hypoxia and inappropriate cell apoptosis are discussed as contributing factors ([@B300]).

Interestingly ponies heal better and faster than horses, with ponies yielding a quicker and more intense inflammatory response and an improved resistance to infection as compared to horses ([@B300]). Some of the most important advantages and disadvantages of using horses as model animals are summarized in [Table 2](#T2){ref-type="table"}.

###### 

Advantages and disadvantages of the horse as a model.

  **Advantages**                                                                                                                                     **Disadvantages**
  -------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  Largest of the models: Multiple large (critical size) defects and serial sampling possible                                                         Ethical concerns -- companion animals
  Functional correspondence of equine SDFT and human Achilles tendon                                                                                 Different breeds, not usually purpose-bred for research
  Thickness of the knee cartilage is similar to the human                                                                                            Costs- Special facilities needed for housing, surgery, imaging, necropsy, etc.
  Imaging plus validated scoring approaches                                                                                                          Non-weight-bearing postoperatively is not feasible
  Arthroscopy (also second look) plus validated scoring approaches                                                                                   Restrictive annotation status and availability of equine specific antibodies, molecular tools and markers
  Controlled postoperative exercise programs and rehabilitation using treadmills and horse walkers to support standardization are well established   Weight − biomechanical strains, which far exceed those considered physiologic in humans
  Well characterized temporal pattern of healing                                                                                                     
  Equine aging well documented                                                                                                                       
  Clinical need − naturally occurring disease                                                                                                        

Another challenge of using horses as animal models, particularly for orthopedic disease, is so called supporting limb laminitis (SLL). Laminitis is a disorder of the tissue suspensory apparatus which suspends the distal phalanx to the inside of the horse's hoof wall. SLL of the contralateral or supporting limb occurs when horses are forced to bear weight predominantly unilaterally (with the supporting limb) for prolonged periods, due to a severe, unilateral lameness. Mechanical loading or overloading of the supporting limb is the primary factor in its pathogenesis ([@B18]; [@B278]).

Sheep as Animal Models {#S4}
======================

General Considerations {#S4.SS1}
----------------------

Domestic sheep (*Ovis aries*) provide unique opportunities in research as an experimental and pre-clinical animal model ([@B147]; [@B128]; [@B3]) because of their availability, low costs and acceptance by the society as a research animal ([@B86]). Sheep are docile, easy to handle and relatively inexpensive with respect to housing and feeding. Their size (50−90 kgs) is more similar to humans than small animal models, lending themselves to repeated sampling from different anatomical structures over an extended period. Their size is ideal for clinical imaging modalities designed for humans such as MRI or CT (which are limited with other large animal models like the horse). At the same time, it allows for testing surgical procedures and medical devices in animals similar to human-size (e.g., bioengineered constructs, pacemakers, stents). On the other hand, sheep housing requires more space (barns for pens) which are not widely available. The commercial availability of molecular tools (e.g., antibodies) is also more limited than for rodents although these are increasing. Nonetheless, the practical disadvantages of the sheep as an experimental model do not make it inaccessible. Based on the aim of the study, the potential benefits may compensate its technical limitations. The publication and annotation of the sheep genome ([@B169]) should improve the amount of commercially available reagents, thus facilitating the use of the ovine model in future studies. Concomitantly, the annotation of the sheep genome could support the development of useful biological tools for sheep as genetic models of human diseases (e.g., Huntington's Disease) ([@B290]). Moreover, anesthesia and surgical equipment in sheep is more similar to humans than other large animals (like horses) and small rodents: Hence, using sheep does not require significant investment in large and specialized handling equipment, or surgical tables. At the same time, sheep can be sourced relatively easily and at low cost and they are considered as a socially acceptable animal model for research that raises fewer ethical issues than companion animals ([@B100]; [@B307]).

Sheep are used as models for a wide range of pathologies: cardiovascular diseases ([@B87]; [@B301]), orthopedics ([@B188]; [@B370]; [@B85]; [@B240]; [@B266]), respiratory function ([@B245]) and reproductive or pregnancy disorders ([@B7]; [@B260]). A major reason is that ruminants, as compared to rodents, share more anatomical and physiological characteristics (with exception of the digestive tract − testing efficacy of drugs may be complicated by the 4-stomach system and uptake dynamics which defer from human gastrointestinal tract characteristics) with humans ([@B316]). This makes the sheep a useful model for preclinical and translational studies in fields of Tissue Engineering and Regenerative Medicine.

Musculoskeletal Disorders {#S4.SS2}
-------------------------

Sheep have anatomical and biomechanical features relatively similar to humans (bone composition, weight, joint structure and architecture) which allows for good simulation of healing and remodeling processes of bone or cartilage tissue ([@B271]; [@B353]). In addition, arthroscopic evaluation is possible in the sheep due to the size of their stifle joints. Therefore, the ovine species is the most commonly used large animal model in orthopedic research including studies on: cartilage repair ([@B266]), meniscal repair ([@B159]; [@B364]), osteochondral tissue engineering ([@B310]), tendon defects ([@B71]; [@B230]), osteoarthritis ([@B275]; [@B140]), and osteoporosis ([@B85]) among the others.

Sheep have been involved in studies for treating critical-sized bone defects using scaffolds with or without Mesenchymal Stem cells (MSCs). These treatments were shown to enhance bone formation and improve mechanical properties if compared to gold standard reparative methodologies like bone grafts ([@B188]; [@B60]; [@B109]; [@B25]; [@B240]; [@B291]).

Although the ovine knee cartilage differs in thickness to human cartilage (0.7−1.7 mm and 2.35 mm, respectively), it provides a close match regarding mechanical properties for preclinical studies ([@B120]; [@B59]; [@B244]). Tissue engineering approaches including different cell sources (as MSCs or chondrocytes) have been widely tested in the sheep for chondral/osteochondral defects ([@B212]; [@B140]). Cells can also be applied with scaffolds of different nature to improve and support regeneration (Chitosan, type I/III collagen, b-TCP, collagen hydrogels) ([@B27]; [@B311]; [@B85]). For example, [@B154] used a biphasic collagen-GAG scaffold loaded with MSCs in a full-thickness osteochondral defect boosting cartilage repair while [@B395] used a 1:1 chitosan-collagen scaffold seeded with human MSCs for articular cartilage regeneration ([@B154]; [@B395]). Recently, a bilayered scaffold to simulate the bone-cartilage interface (chondral and bone tissue components) has been developed and tested in sheep ([@B314]; [@B103]).

Furthermore, regenerative strategies for osteoarthritis (usually induced by meniscectomy) have been investigated in sheep ([@B340]; [@B84]; [@B108]). Of particular interest are the studies on scaffolds for meniscal repair because of its shared characteristics with the human meniscus (cellularity, vascularity, biomechanics) ([@B55]; [@B38]). [@B138] tested a silk fibroin scaffold as a meniscal implant after meniscectomy in sheep showing its biocompatibility ([@B138]).

Spontaneous cartilage lesions (including osteoarthritis) have been observed in the sheep without experimental induction ([@B158]; [@B370]; [@B192]). These are especially prevalent in aging sheep and might better recapitulate the human ailment than artificially created cartilage defects.

Sheep, like horses, are ideal candidates for tendinopathy modeling, but cheaper and easier to handle and house. [@B230] showed the treatment efficacy of MSCs, with or without PRP (platelet rich plasma), on collagenase-induced tendinitis in the superficial digital flexor tendon, with a better structural organization of the repaired tendon ([@B230]). [@B83] tested the use of chitosan-PRP implants in an ovine acute defect model to mimic rotator cuff injuries. The implants led to an extensive bone remodeling and tissue ingrowth at the tendon-bone interface level ([@B83]).

Nervous System {#S4.SS3}
--------------

The ovine species also serves as an adequate and effective model to study peripheral nerve regeneration, because of the similar nerve size ([@B344]) and similar regenerative behavior ([@B146]; [@B125]) compared to humans ([@B86]).

Apart from conventional autografts and allografts for repairing peripheral nerve injuries in sheep ([@B119]; [@B234]), tissue engineering techniques have also been applied. [@B50] applied a commercially available biodegradable scaffold with MSCs or PRP to reconstruct damaged radial and tibial nerves. The addition of MSCs, with or without PRP, led to the production of myelinated nerve fibers at the distal and proximal level with fiber regeneration and functional recovery after 6 months ([@B50]). [@B302] compared the use of autologous nerve and acellularized vein grafts produced from spider silk. The outcomes obtained with the construct where similar to the nerve autograft results: axonal regeneration and myelination were achieved at 10 months ([@B302]).

Using sheep models, MSCs were shown to play a reparative role in intervertebral disc regeneration. Injection of MSCs led to a reduction of degeneration of the discs compared to the control group ([@B118]; [@B76]).

Heart Disease {#S4.SS4}
-------------

Sheep have been frequently used as model for cardiovascular applications, especially for testing heart valves which have similar valve anatomy to the human and the sheep size permits access to the pulmonary and aortic valve. [@B183] developed an *in-situ* heart valve replacement for the pulmonary valve using a resorbable synthetic graft. 12 months post-implantation the tissue-engineered valve was shown to be colonized by host cells and replaced by newly formed tissue with a mature organization of the extracellular matrix without any sign of valve calcification ([@B183]).

Cell therapies with MSCs have further been applied in acute myocardial infarction models to improve myocardial function. The inoculation of cells has been demonstrated to be safe, to increase vasculature, and to reduce fibrosis in the infarcted heart ([@B156]). [@B301] showed that the injection of MSCs and endothelial cells (ECs) promoted angiogenesis and cardiac function, supposing that one of the mechanisms of action of the MSCs might lie in their differentiation potential toward the endothelial lineage ([@B301]).

Also, different tissue engineering approaches for the development of preclinical vascular grafts have been tested in the sheep model ([@B73]; [@B9]; [@B124]; [@B189]).

Tissue Engineering Applications in Other Systems {#S4.SS5}
------------------------------------------------

The ovine model has further been deployed to test regenerative approaches for treating respiratory disorders (similar airways structure and lung size to humans):

MSCs led to a reduction of inflammation and oedema and an improved oxygenation in sheep models of acute respiratory distress ([@B10]; [@B186]). In an induced emphysema model, the infusion of MSCs resulted in blood reperfusion of the damaged tissue and the formation of new extracellular matrix ([@B163]).

Recently, [@B174] have tested the transplantation viability of decellularized kidneys in sheep.

The sheep model has also been described for wound healing studies because it allows for the creation of relatively large and deep wounds to mimic the typical scenario of traumatic injuries like burn injuries or decubitus ulcers. [@B231] used a sheep second intention wound healing model and showed how the intradermal and topical application of allogeneic MSCs led to a better re-epithelialization and dermal structure as compared to the control group at 42 days after wounding ([@B231]). The identical model was recently used by [@B161] to compare secondary intention healing of wounds, treated with a topical application of commercially available hyaluronic acid, Manuka honey or Acemannan gel ([@B161]).

In a similar ovine wound model, [@B205] applied native spider silk as a wound dressing to test its biocompatibility and regenerative capacities ([@B205]). [@B236] used bioengineered autologous skin substitutes to treat myelomeningocele in a spina bifida repair model. The skin substitute, made of hydrogel colonized by autologous fibroblasts and keratinocytes, was transplanted in utero. The skin substitutes showed a normal histology after 1 month ([@B236]).

Recently, [@B232] evaluated the use of a low-temperature atmospheric pressure plasma (ionized gas) as a treatment for extensive wounds in a sheep model. The plasma stimulated cell proliferation, angiogenesis and the development of skin adnexa; concomitantly, it reduced bacterial infection and inflammation ([@B232]).

A different tissue engineering approach to treat myelomeningocele was used by Watanabe et al. to treat spina bifida wounds with a gelatin/collagen sponge hybrid scaffold ([@B379]).

Embryonic/Fetal Healing {#S4.SS6}
-----------------------

True "scarless healing" is observed only in embryos and early fetus ([@B345]). The restitutio ad integrum in embryos ([@B23]) is considered an ideal situation unmatched by any treatment regimen in adults. Therefore, an increasing amount of research studies is performed in embryos or fetal animals. To study the mechanism of fetal regeneration, relevant *in vivo* as well as *in vitro* models are required. Fetal sheep share many important physiological and developmental characteristics with humans and have hence proven themselves invaluable models for mammalian physiology ([@B5]; [@B167]). Sheep frequently carry twins, which allows using one twin as uninjured control on a background of low genetic variation to enable differentiation between regular fetal development and fetal response injury.

Furthermore, their long gestational period (150 days) provides sufficient temporal resolution to translate findings obtained in sheep into human parameters ([@B5]; [@B167]).

Fetal sheep have a fully functioning immune system by 75 days of gestation (gd) ([@B99]). They produce leukocytes by 32 gd ([@B313]), TNF and Il-1 as early as 30−40 gd ([@B96]) and obtain the capability to form significant amounts of specific antibodies in response to antigenic stimulation as early as 70 gd ([@B329]). Fetal lambs reject orthotopic skin grafts and stem cell xenotransplants placed post 75−77 gd ([@B328]) and mount an inflammatory response to injury by gestational day 65 ([@B272]; [@B262]; [@B150]; [@B259]).

For all these reasons, results obtained in the fetal lamb have been directly applicable to the understanding of human fetal growth and development and are highly predictive of clinical outcome in a variety of applications including in utero stem cell transplantation ([@B206]; [@B5], [@B4]; [@B296]; [@B193]; [@B180]; [@B167]).

Additional Considerations Regarding Sheep {#S4.SS7}
-----------------------------------------

Due to their special stomach system (4 stomachs: rumen, reticulum, omasum, and abomasum) bio-availability and efficacy of drugs administered orally is questionable for the human GI tract. Moreover, prolonged inappetence and application of non-steroidal anti-inflammatory drugs, antibiotics or both resulting in sustained high acidity in the abomasum may cause abomasal ulceration. Also stress, high dietary fiber and inadequate dietary fiber are believed to play a role ([@B91]; [@B121]).

Therefore, pain management and anti-microbial management have to be planned carefully and adapted to meet the special requirements of sheep ([@B211]; [@B371]). Sheep guidelines for pain assessment by facial expression are available ([@B142]) which may help managing pain.

Some of the most important advantages and disadvantages of using sheep as model animals are summarized in [Table 3](#T3){ref-type="table"}.

###### 

Advantages and disadvantages of the sheep as a model.

  **Advantages**                                                               **Disadvantages**
  ---------------------------------------------------------------------------- -------------------------------------------------------------------------------------
  Multiple large (critical size) defects and serial sampling possible          Different breeds, not usually purpose-bred for research
  Thickness of the knee cartilage is similar to the human                      Special facilities needed for housing, surgery, imaging, necropsy, technical skills
  Docile to handle                                                             Non-weight-bearing postoperatively is not feasible but can modulate with location
  Availability, and acceptance by the society as a research animal             Different stomach system than humans
  Size is more similar to humans than small animal models or horses            Ethical concerns but minor compared to companion animals
  Publication and annotation of the sheep genome                               Costs
  Imaging plus validated scoring approaches available (esp. for orthopedics)   
  Arthroscopy (also second look) plus validated scoring approaches             

Pigs as Animal Models {#S5}
=====================

General Considerations {#S5.SS1}
----------------------

Porcine models present the advantage of having similarities with the human in terms of gastrointestinal anatomy, metabolism and physiology ([@B70]). When compared with other farm animals, pigs acquire early sexual maturity, sizeable litter size and have a quick reproduction time. They also breed year-round, which makes them highly suitable for biomedical research programs ([@B293]). Due to these characteristics and the anatomical and physiological similarities, and also their size (young pigs have a size and body weight similar to human adults), pigs are widely used as models in organ transplantation and other surgical procedures ([@B173]; [@B52]; [@B229]; [@B145]; [@B342]; [@B375]), or as preclinical models in drug discovery ([@B350]; [@B321]), and numerous naturally occurring and generated genetic models of human disease ([@B350]; [@B293]). Hence, and similarly to the areas of medicine described above, the pig is gaining traction as the large animal model of choice for the study of tissue engineering and regenerative medicine products and applications, and of biomechanic studies. A good evidence of this is the steep rise in the number of publications in these broad areas in the past 30 years ([@B65]).

Drug Discovery and Toxicology {#S5.SS2}
-----------------------------

Traditionally, animal models used for preclinical testing of new drugs and toxicology studies have been rodents, mainly mice and rats, for the primary screening studies. Nonetheless, because translation from rodents into humans is often not fully realized, regulatory agencies also demand the use of non-rodent models. Pigs are increasingly being used as an alternative to dogs or primates, the previous nonrodent species of choice ([@B350]). However, due to growing pressure from the public, there has been a drive for new alternatives. The pig has been favored as a suitable alternative, since they have many anatomical and physiological features valuable for translational research and are already well accepted as one of the gold standard surgical models ([@B350]). In particular, the cardiovascular system, skin and digestive tract closely mimic the human. Due to these similarities the metabolism and toxic effects of chemicals and drugs in pigs may more closely resemble the effects in man than some other laboratory animals. The minipig has been introduced recently as another alternative ([@B74]) which is frequently used due to its smaller size and easier handling for drug discovery and toxicology applications ([@B237]), boosted by the publication of the RETHINK project ([@B115]). Furthermore, the porcine CYP450 system has been studied and partially described, and their metabolic pathways have been found to be relatively analogous to humans, with substantial overlap in substrate specificity ([@B333]; [@B264]).

Generated Genetic Models {#S5.SS3}
------------------------

With the advent of DNA recombination and gene editing technologies, modifying the pigs genome has enabled its use as a genetic model of numerous human diseases ([@B113]; [@B392]). This is reflected in the multiple pig strains developed to study, amongst others, cancers, Duchenne muscular dystrophy, autosomal polycystic kidney disease, Huntington's disease, spinal muscular atrophy, cystic fibrosis, hemophilia A, X-linked severe combined immunodeficiency, retinitis pigmentosa, Stargardt's Disease, Alzheimer's disease, various forms of diabetes mellitus and cardiovascular diseases ([@B113]; [@B307]; [@B392]; [@B287]). From these, the RAG2 or RAG2/IL2RG KO pigs are particularly relevant for biomedical research, since they can accept xenografts and/or human bioengineered tissue/organs ([@B29]).

Transplantation Models {#S5.SS4}
----------------------

The pig has been used as a teaching and research animal model in surgery in the past decades. Starting in the 1990s, it became so prominent in academic and surgical training that it can be regarded as default model for non-survival surgical teaching classes, substituting the dog ([@B349]). Its ubiquitous presence and use in academia, enabled also its widespread adoption in multiple models of liver, lung, heart, pancreas and kidney transplantation ([@B233]; [@B229]; [@B145]; [@B114]; [@B224]). Furthermore, in transplantation medicine, the pig has also been proposed as xenograft donor, where porcine grafts have been transplanted into non-human primates with different degrees of success ([@B309]; [@B137]). This has encouraged several research groups to target the porcine genome to eliminate the major xeno-antigen(s) recognized by human natural antibodies, in a so-called effort of humanizing the pig ([@B195]; [@B289]; [@B288]; [@B168]). If ultimately realized, these procedures might enable the future xenotransplantation of porcine organs into humans as the main approach for transplantation medicine. Efforts are currently being taken to reduce the risk of viral zoonosis from porcine endogenous retrovirus (PERV), either by pharmacological treatment of PERV or by inactivating it with gene editing tools ([@B81]; [@B273]). Finally, other efforts have been concentrated on porcine uterus, urethra, kidney or liver bioengineering for transplantation ([@B13]; [@B347]; [@B46]; [@B330]). All these are an important testimony of the relevance of the pig as a vital translation research animal model.

Skin {#S5.SS5}
----

The minipig has been used as a model in the development of dermatological products ([@B255]; [@B390]), and more recently, as a model for microbiome studies ([@B101]). As omnivores with an analogous gastrointestinal tract to humans, the well-characterized fecal microbiota of young and adult domestic pigs and other strains used in research also offers compositional resemblances to that of humans ([@B286]; [@B394]). Remarkably, many of these strains are used to investigate diet-induced obesity in genetically susceptible individuals and the same modifications (e.g., an increase in the ratio of Firmicutes to Bacteroidetes) observed between lean and obese humans are emulated in these pig models during the development of obesity ([@B285]).

Musculoskeletal Disorders {#S5.SS6}
-------------------------

In this particular area of biomedicine, the pig is experiencing a higher increase in adoption when compared to other large animal models ([@B65]) and several studies have been published assessing interspecies and interstrain differences in the anatomy and biomechanics of tissues and joints and their applicability in tissue engineering and regenerative medicine studies. Porcine models have a long history of use for studying the biomechanics of specific joints like the knee or the temporomandibular joint (TMJ), and specific tissues, including bone, cartilage, and ligaments ([@B389]; [@B348]; [@B299]; [@B265]; [@B277]). Hence, the pig has been used with success to test the efficacy of bone substitute biomaterials ([@B204]) and in osteochondral defect studies ([@B134]; [@B246]). Similarly, extensive research has been conducted with the pig in tendon and ligament repair as reviewed by others ([@B48]).

Pigs have also been used recently as a model of amyotrophic lateral sclerosis (ALS). This research has been based on the use of transgenic pigs with a mutated human copper/zinc superoxide dismutase 1 gene that mimics the human neurodegenerative disease in these pigs ([@B56]; [@B391]). Similarly, a pig model of Duchenne muscular dystrophy (DMD) has been created by Klymiuk et al. by deleting DMD exon 52 in male pig cells by gene targeting. The offspring generated by nuclear transfer exhibit absence of dystrophin in skeletal muscles, progressive dystrophic changes of skeletal muscles with impaired mobility, muscle weakness and a maximum life span of 3 months due to respiratory impairment ([@B185]).

Additional Considerations Regarding Pigs {#S5.SS7}
----------------------------------------

Pigs suffer from porcine malignant hyperthermia also known as porcine stress syndrome which is characterized by hyperthermia triggered by stress, certain anesthetic agents or intense exercise and may lead to sudden death ([@B270]). Some of the most important advantages and disadvantages of using pigs as model animals are summarized in [Table 4](#T4){ref-type="table"}.

###### 

Advantages and disadvantages of the pig as a model.

  **Advantages**                                                                                                                     **Disadvantages**
  ---------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------
  Size of the pigs: Multiple and longitudinal measurements possible                                                                  Ethical concerns but minor compared to companion animals
  Functional equivalence of various diseases in men and pigs                                                                         Special facilities needed for housing, surgery, imaging, necropsy
  Genetic variation between breeds (cfr human population), moderate genetic variation within breeds (naturally occurring diseases)   Non-weight-bearing postoperatively is not feasible but can modulate with location
  Imaging plus validated scoring approaches available (esp. for orthopedics)                                                         Costs
  Arthroscopy (also second look) plus validated scoring approaches                                                                   

Companion Animals as Animal Models {#S6}
==================================

General Considerations {#S6.SS1}
----------------------

The importance of companion animals to serve as models for human disease has received significant attention through the One Health initiative which aims to "break through the species barrier" in a drive toward a better link between medical and veterinary research for the benefit of both the human and veterinary patient ([@B58]).

While the definition of companion animals covers a range of animals this article extends only to the dog and cat as models, as they share remarkable similarities with the human and provide unique opportunities for developing advanced therapeutics.

One of the main reasons why dogs returned as a focus of genetic research is related to the specific population structure that has been created over the past 150−200 years.

To fully appreciate and exploit the biomedical potential of dogs (both as pets and as experimental animals), some insight into the unique canine population structure is necessary. Domesticated dogs were subjected to rigorous breeding selection, for instance for behavioral traits and/or specific morphological features such as excessive muscle formation, short limbs or a specific coat color ([@B199]). Illustrative for this process is the extreme size variation, by far the largest of all mammals known, ranging from less than 1 kg for Chihuahua dogs to over 70 kg for Irish wolfhounds and Neapolitan Mastiffs. This selection process was intensified in the last two centuries and resulted in isolated genetic populations of dog breeds ([@B281]). Whereas the genetic variation over the various breeds remained intact, the reduced genetic variability within breeds worked as a genetic amplifier and offers "genetic dissection microscope" for research ([@B207]; [@B281]; [@B199]; [@B368]). Together with the selection for unique traits, an increased risk for the development of specific inheritable disorders arose within breeds, providing physiologically relevant models corresponding to human conditions. To make the best out of the current situation may be to exploit the downside of inbreeding as a gene-discovery instrument for causative and modifier genes involved in complex diseases and/or rare diseases.

Canine Inherited Copper Toxicosis {#S6.SS2}
---------------------------------

The trace element copper is indispensable for critical biochemical processes such as enzyme function, for instance cytochrome c oxidase (part of the respiratory enzyme complex) or superoxide dismutase (conversion of superoxide radicals into molecular oxygen or hydrogen peroxide) ([@B162]). Since copper is a transition element (reduced as Cu+ and oxidized as Cu^2^+) its Jekyll and Hyde character becomes evident in the involvement in chemical reactions leading to the production of reactive oxygen species. In a Fenton reaction, Cu^+^ catalyzes the formation of the highly reactive hydroxyl radical (OH**^.^**). In the converse Haber-Weiss reaction Cu^2+^ inactivates the damaging superoxide radical O~2~. Therefore, regulation of its intracellular free concentrations is of utmost importance and needs to be controlled within very narrow limits ([@B178]). Several inherited copper-related diseases are diagnosed in men such as Menke's Disease (copper deficiency disorder), Wilson Disease (WD, copper accumulation), and the very rare Indian childhood cirrhosis ([@B352]), endemic Tyrolean infantile cirrhosis ([@B263]), and idiopathic copper toxicosis ([@B317]). These all are rare diseases posing specific obstacles for researchers aiming to dissect molecular pathways and for rational drug design. These obstacles include limited financial resources compared to diseases affecting large numbers of patients, smaller patient cohorts for clinical phase 1−3 studies, difficulties for properly matched case-control studies in genetics and molecular signaling studies.

Copper disorders also affect sheep and dogs ([@B363]; [@B143]; [@B122]). Deleteriously increased levels of hepatic copper are described in a number of dog breeds including Bedlington terriers, Skye terriers, West-Highland White terriers, Doberman, Dalmatians and Labrador retrievers ([@B363]; [@B144]; [@B358]; [@B357]; [@B382]; [@B153]). In 1999 genetic mapping studies revealed that the copper toxicosis locus within Bedlington terriers was located on canine chromosome 10. 3 years after positional cloning a 13kB deletion covering exon-2 of the murr1 gene was identified as the causative mutation for Bedlington terrier copper toxicosis ([@B366], [@B365]). The causative role of murr1 mutations in WD is a matter of debate. Stuehler et al. found an association between murr1 mutations and WD, whereas two other papers did not detect a correlation between murr1 mutations and WD ([@B346]; [@B214]; [@B388]). This novel gene product, currently called COMMD1 (COpper Metabolism Murr1 Domain-containing protein 1) had no known function at the time it was discovered, and the mechanism of action related to hepatic copper accumulation remained enigmatic. The discovery that COMMD1 and ATP7B interact intracellularly revealed a mechanistic link between COMMD1 protein and copper toxicosis, later confirmed for the Menkes Disease protein ATP7A ([@B77]; [@B377]).

The discovery of the COMMD1 mutation and subsequent investigations into functions of COMMD1 is an intriguing example for a useful exploitation of inbred dog strains to reveal novel molecular and genetic pathways. Genetically speaking the big advantage of canine genetics to benefit human genetics is the ease to discover modifier genes. This is a needle-in-a-haystack technology in men even today, but the specific genetic population structure in inbred dogs clearly facilitates this approach.

Labrador retrievers are among the most popular breeds in the Western world.

It was already known for a long time that approximately one in every three first-line relatives of Labradors retrievers with copper toxicosis had elevated copper levels ([@B153]). This pushed investigations into whether or not Labrador retrievers were new model animals for WD and as a consequence propelled genetic studies ([@B112]). A SNP based genome-wide association study aiming to discover the genetic background of inherited copper toxicosis in Labrador retrievers included over 200 Labrador retrievers (154F, 81 M cases; 37F and 22 M as replication cohort) in the Netherlands that were genotyped on the 170k SNP Illumina Canine HD Bead Chip ([@B111]). For details on the mechanism of action of these mutations the readers are referred elsewhere ([@B111]). Approximately 12% of the phenotype can be explained by two mutations identified in Labrador retrievers. Since mutations in these genes were already described in copper-related disorders, it remains to be seen what other as-yet-unidentified genetic mutations will be discovered.

This genetic study clearly illustrates the power of the canine model. Explaining 12% of the phenotypic variation with an ample 250 dogs doesn't even remotely resemble the number of human patients used to explain similar percentage for age at menarche, Inflammatory Bowel Disease (IBD) and Rheumatoid arthritis (RA) for which over 100,000 individuals were included ([@B98]; [@B276]; [@B210]).

The examples prove that due to the specific population structure of inbred dog breeds, genetic studies can be successfully performed even for rare and/or complex genetic diseases.

In order to investigate COMMD1-deficient dogs as a preclinical model for liver stem cell transplantations, a breeding colony of five COMMD1 deficient dogs was created on a Beagle background and followed for over 4 years ([@B106], [@B107]; [@B105]). This model for inherited copper toxicosis has some practical features specifically relevant for pre-clinical studies that aim to investigate surgical procedures. In contrast to mouse models, that are sacrificed for every liver measurement, the dogs' size allowed for a true longitudinal study permitting liver biopsy sampling twice a year.

Heart Disease {#S6.SS3}
-------------

The most prevalent non ischaemic cardiomyopathies in humans are hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), reported to affect 1 in 500 and 35 in 100,000 people, respectively (2017, [@B151]). Arrhythmogenic ventricular cardiomyoapthy (AVC) is also recognized as an important and distinct form of cardiomyopathy. Together they are associated with mechanical and/or electrical dysfunction and manifestations of the disease can range from microscopic alterations in cardiomyocytes and cardic fibroblasts to heart failure (which results in inadequate tissue perfusion and fluid retention) and arrhythmia which may cause sudden death. In veterinary species HCM is the most common feline cardiac disease affecting around 1 in 15 cats and DCM is the second most common cardiac disease in dogs and can affect a wide variety of breeds including the Doberman where its cumulative prevalance is as high as 44%. AVC has been comprehensively described in the Boxer breed at the molecular, cellular and clinical levels. All three cardiomyopathies share striking pathological and clinical similarities with the human disease. While there has been progress in the management of the symptoms associated with these cardiomyopathies in human patients, the actual disease processes remain a challenge to treat as there are few therapies that target the underlying pathology. There has therefore been an emphasis on the use of regenerative cellular therapies, although most studies have focused on ischaemic myocardial disease using mesenchymal stem cells (MSCs) derived mostly from bone marrow or adipose tissue. Stem cells derived from myocardial tissue have more recently been developed and have been tested in a number of induced disease models. A comparison of MSCs and cardiosphere derived cells (CDCs) suggests that CDCs are more efficacious in their ability to regenerate the myocardium ([@B203]) and phase 1 clinical trials using autologous CDCs show encouraging results ([@B30]; [@B218]; [@B221]).

The development of cell-based approaches in the feline and canine clinic will have significant benefits for translation in human cardiomyopathy treatment.

Human and Feline Hypertrophic Cardiomyopathy {#S6.SS4}
--------------------------------------------

Hypertrophic cardiomyopathy is the most common cardiomyopathy in both humans and cats with a prevalence of approximately 0.1−0.2% and 16%, respectively ([@B227]; [@B283]; [@B322]; [@B160]). There is increasing literature that supports the cat as an animal model of human HCM and evidence suggests it is essentially the same disease in both species ([@B226]). HCM is characterized by left ventricular hypertrophy in the absence of systemic causes and can result in heart failure and/or sudden death. In humans genetic mutations are identified in 60% of HCM cases, mainly in genes encoding sarcomeric proteins ([@B43]). HCM in the cat is also considered to have a familial cause although only two causative mutations have so far been identified ([@B226]), in contrast several hundred have been identified in human patients. Both of the feline mutations occur in the cardiac myosin binding protein C (MYBPC3) gene, one of which occurs in the Maine Coon breed (A31P mutation) and the other in the Ragdoll breed (R820W mutation) ([@B251], [@B250]). It is of interest to note that one specific non-truncating mutation, MYBPC3/R820W, that occurs in Ragdolls has been identified in a human family with HCM ([@B305]; [@B32]). The role sarcomeric mutations play in the development of HCM in non-pedigree cats requires further investigation.

The underlying molecular pathogenesis driving HCM remains to be elucidated although a common pathway is thought to exist in both humans and cats in which altered calcium handling within the myofilaments enhances calcium sensitivity, causing maximal force production and energy deficiency promoting mitochondrial dysfunction, cell death, fibrosis and cardiomyocyte hypertrophy ([@B157]; [@B228]; [@B341]; [@B306]).

Studies using myocardial tissue from a cat homozygous for the MYBPC3/R820W mutation suggest that increased myofilament calcium sensitivity can occur in the absence of haploinsufficiency, which is common feature in human MYBPC3 mutations ([@B247]). Increased myofilament calcium sensitivity was also seen in other HCM affected cats of unknown genotype but not in unaffected cats. An additional feature of the study was that the calcium sensitivity of the sarcomere is uncoupled from the phosphorylation status of troponin I, although it remains unclear how mutations outside the troponin complex cause this uncoupling phenomenon. The reasons clearly are complex but the similarities at the molecular level show the cat to be a highly relevant natural disease model for human HCM for deciphering the mechanisms. Targeting the disease with Epigallocatechin-3-gallate, for example can reverse troponin I phosphorylation uncoupling in cat HCM ([@B247]) which has been replicated in human HCM samples ([@B326]).

Such studies highlight the need to identify detailed molecular mechanisms for precise drug targeting. However, there are practical limitations with obtaining sufficient heart tissue and the survival of isolated primary cardiomyocytes is poor. Induced pluripotent stem cells (iPSC) or embryonic stem cells (ESCs) represent an alternative and robust source for preparing cardiomyocytes. The development and use of human ESCs represents an ethical dilemma and while less of an issue in veterinary species, there are only two reports of ES-like cells from cats, but these do not replicate indefinitely in culture unlike true ES cells. iPSCs on the other hand do not have the concerns associated with ESCs and can be relatively readily prepared from somatic cells.

Feline iPSCs have recently been reported for the first time by our group, the development of which represents a significant step in the generation of iPSC derived cardiomyocytes from a veterinary species ([@B95]). It paves the way for generating further cell lines from feline patients carrying the HCM causing MYBPC3/R820W mutation to test novel therapeutics for modifying the disease. iPSCs can further be manipulated with technologies such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) to enable targeted genetic manipulation of both normal and diseased patient cell lines ([@B44]; [@B312]).

iPSCs derived from patients with HCM or iPSCs with a genetic mutation inserted using CRISPR to model HCM, display characteristics of hypertrophic cardiomyocytes in culture ([@B261]) suggesting the suitability of the approach in establishing cell models of HCM. The availability of feline iPSC lines will enable dissecting out the molecular mechanisms of HCM enabling targeted drug screening where promising molecules can be rapidly assessed in the feline clinic with the potential of swift translation to human patients.

Human and Canine Dilated and Arrhythmogenic Ventricular Cardiomyopathy {#S6.SS5}
----------------------------------------------------------------------

DCM is the third most common inherited myocardial disease in humans with an estimated prevalance of 0.35% and some 2.5 million cases globally affected^[6](#footnote6){ref-type="fn"}^. It is the second most common cardiac disease in dogs and accounts for 10% of canine cardiac diagnosis ([@B97]). As with feline HCM there are remarkable similarities in the pathophysiology of DCM between human and dog. Although it is a heterogenous disease it is characterized by progressive enlargement of the left ventricle that leads to reduced systolic function, congestive heart failure and a variety of arrhythmias. Underlying causes include systemic disorders such as hypertension and atherosclerosis in humans but is also now recognized as a primary genetic disorder that may manifest with or without accompanying predisposing factors. Giant dog breeds such as the Great Dane and Newfoundlands are at risk and a genetic basis has been proposed in some dog breeds including the Doberman Pinscher and Boxer in which the disease is both common and severe with a cumulative prevalence in European Dobermans \>8 years of age of 44% ([@B235]; [@B331],[@B332]). A genetic deletion in the Pyruvate Dehydrogenase Kinase 4 (PDK4) gene has been reported. PDK4 is critical in regulating mitochondrial energy metabolism as the genetic deletion predisposes affected individuals to developing DCM as it results in chronic energy attenuation ([@B248]). More recently a missense variant in the titin gene has been reported in affected Doberman pinscher dogs negative for the PDK4 mutation. The Boxer breed has a distinct form of cardiomyopathy that closely resembles AVC in humans ([@B374]). A causative mutation in the striatin gene has been identified in Boxer dogs in the United States but this was not seen in the UK population ([@B249]; [@B51]). The role of genetics in other dog breeds with DCM remain to be better described.

Histopathological observations of the myocardium show that canine cardiomyopathy displays either an attenuated wavy fiber type and fibro-fatty infiltration type ([@B360]) with the latter highly similar to AVC in humans. These findings emphasize the comparable pathological changes and clinical presentation between the two species ([@B16]; [@B252]; [@B372]). The pathophysiologic mechanism underlying AVC is thought to involve mechanical and electrical decoupling and cardiomyocyte apoptosis ([@B383]) which with the fibro-fatty replacement of the myocardium are considered primary drivers for risk of arrhythmia and sudden cardiac death. Dogs that survive develop progressive ventricular dilation and systolic dysfunction leading to congestive heart failure ([@B383]; [@B252]).

There have been efforts to use stem cells for the treatment of cardiac disease in humans spurred by observations that the adult heart processes regenerative ability ([@B64]; [@B268]). A number of clinical trials are under way or completed using adipose or bone marrow derived mesenchymal stem cells (MSC) although these are predominantly for ischaemic disease. One published study in Doberman pinchers with DCM administered allogeneic adipose derived MSCs that were virally transfected to overexpress stromal derived factor-1 to enhance homing and engrafting capabilities of endogenous MSCs to the myocardium ([@B292]). Although no significant improvements in survival rates were found at 2-year follow up, the study demonstrated that the dog model of naturally occurring DCM can be utilized to overcome a number of challenges for regenerative therapies. There is increasing interest in CDCs as they appear to possess a superior ability to regenerate the myocardium ([@B203]) compared to MSCs. CDCs are a heterogenous cardiac stem cell population which display features typical of stem cells such as forming clones, self-renewal and commitment to multiple lineages ([@B171]; [@B57]; [@B53]; [@B148]). The use of CDCs clearly is not practical because of the need to sample from the patient and also because of expansion of cells from a diseased individual which adds to patient risk, time and treatment costs. Allogeneic cells offer an alternative off-the-shelf-product but risks include immunological complications that may lead to graft versus host disease. Work in a rodent model and other induced disease models suggests allogeneic CDCs are non-immunogenic ([@B220]). Allogeneic CDCs have been tested in a small clinical trial in dogs affected with DCM ([@B149]) and no significant adverse effects were reported. Nevertheless, the process of cryofreezing of cell stocks may potentially alter intrinsic properties of the cells as has been shown for MSCs ([@B256]). Effects such as chromosome abnormalities resulting in abberrant cellular activity and risk of tumorigenesis may compromise their clinical use. However we have demonstrated that cryopreservation of dog CDCs does not alter their immunophenotype and cellular characteristics ([@B93]). Furthermore, we have shown at a molecular level that canine CDCs are also immune- privileged similar to the immunomodulatory function of MSCs ([@B94]) and cryopreservation retains this property suggesting they are safe to use *in vivo*.

Musculoskeletal Disorders in Companion Animals {#S6.SS6}
----------------------------------------------

### Osteoarthritis {#S6.SS6.SSS1}

Dog models have long been used to study joint disorders particularly osteoarthritis. The canine model for osteoarthritis has been more commonly used than the horse, sheep or goat model ([@B238]). One of the reasons might be the easier post-operative management and follow up using various exercise regimes on e.g., treadmills ([@B238]). While there are some similarities in cartilage anatomy between humans and dogs, the standing angle in the hindlimb in dogs is much larger. This should be considered when biomechanical aspects are compared and evaluated ([@B238]). As stated previously the cartilage thickness in dogs is 0.6−1.3 mm and cartilage defects are considered to have a critical size at a minimum diameter of 4mm. Experimental OA is preferably induced in the stifle joint ([@B294]; [@B223]; [@B191]), whereas naturally occurring disease is also common in the elbow or hip joint with an estimation prevalence of OA affecting 20% of adult dogs ([@B238]).

With respect to osteoarthritis dogs are divided in two classes, non-chondordystrophic (NCD) and chondrodystrophic (CD) dogs. The last group presents with disproportionally short limbs, caused by aberrant endochondral ossification of long bones. Dachshunds are typical examples. The molecular mechanisms of this short limb phenotype is associated with a retrogene insertion of the FGF4 fibroblast growth factor 4 gene. This leads to elevated levels of FGF3 signaling. Interestingly, whereas CD dogs are more prone to intravertebral disc degeneration (IVDD), the insertion of the retrogene renders short-limb dogs less likely to develop OA in comparison with NC-dog ([@B355]). These examples emphasize the need to carefully select for a specific dog breed for musculoskeletal investigations.

### Intervertebral Disc Degeneration {#S6.SS6.SSS2}

Despite walking on four legs in contrast to men walking on two only, both species develop intervertebral disc degeneration with great similarities and similar prevalence. Link-N is a protein involved in proteoglycan stabilization (beneficial) and is highly homologous between men and dogs. However, neither human link-N nor canine link-N can protect cultured canine intervertebral disc cells form degeneration, whereas human link-N improved glycosaminoglycn deposition in human and bovine chondrocyte-like cell cultures ([@B12]).

In a classcial pre-clinical study a controlled release system for the COX-2 inhibitor celecoxib (cyclooxygenase-2) was tested in a dog model for IVDD ([@B356]). Since celecoxib prevented IVDD progression and reduced inflammation, follow-up studes will be conducted in a clincal study aiming to eliviate the chronic pain associated with low back pain.

### Cranial Cruciate Disease and Meniscal Injury {#S6.SS6.SSS3}

Naturally occurring cranial cruciate disease has been studied extensively in veterinary medicine ([@B67]; [@B24]). It can therefore be stated, that the pathophysiology differs between injuries in humans and canines, because dogs typically suffer from degenerative ruptures ([@B62]) as compared to acute traumatic injuries seen in humans. To study new treatment approaches and validate their success, experimental models with artificially severed cruciate ligaments should be employed ([@B35]).

Dogs also suffer from naturally occurring meniscal pathologies and hence lend themselves as potential translational models to study mechanisms of degeneration or for testing new treatment strategies ([@B190]). The canine meniscus has comparable anatomic features (vascularization, cellularity, collagen structure) and similar permeability to the human ([@B348]*;* [@B82]). However, some differences between canine and human menisci especially with regard to biomechanical properties such as the aggregate- and shear-modulus should be pointed out ([@B348]; [@B141]).

Nervous System {#S6.SS7}
--------------

Cats often serve as models to study spinal cord healing and comparative aspects in neurosurgery ([@B14]*;* [@B20]*;* [@B1]*;* [@B34]). Biomechanical motion analyses using treadmills and force plates as well as electromyography (EMG) are performed to evaluate spine kinematics and muscular properties following experimentally induced spinal cord or cerebral lesions.

Additional Considerations Regarding Companion Animals {#S6.SS8}
-----------------------------------------------------

Dogs and cats are companion animals and pets and as such subject of unprecedented love and care in our society. Therefore, studies involving dogs and/or cats raise more ethical debate than other animal studies. However, most studies in these animals use clinical cases seen in veterinary hospitals and clinics, which highlights the importance of this underused resource for research. Some of the most important advantages and disadvantages of using dogs as model animals are summarized in [Table 5](#T5){ref-type="table"}.

###### 

\(a\) Advantages and disadvantages of canine research in general and hepatology in particular. (b) Advantages and disadvantages of companion animals as models.

  **Advantages**                                                                                                                     **Disadvantages**
  ---------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------
  Size of the dogs: Multiple and longitudinal measurements possible                                                                  Ethical concerns -- companion animals − More of a concern if experimental use
  Functional equivalence of various diseases in men and dogs/cats                                                                    No canine hepatitis virus causally correlated with canine hepatitis
  Large genetic variation between breeds (cfr human population), limited genetic variation within breeds (genetic magnifier glass)   Specific drug intolerances for specific breeds
  Imaging plus validated scoring approaches available (esp. for orthopedics)                                                         
  Dogs: Arthroscopy (also second look) plus validated scoring approaches                                                             Costs
  Dogs: Objective weight-bearing of legs possible (force plate analysis)                                                             Special facilities needed for housing, surgery, imaging, necropsy
  Dogs: Size variations cover new-born human-size until adult size                                                                   Size variation, so drug dosing needs special attention
  Clinical need, large patient population (pets) available                                                                           

Conclusion {#S7}
==========

Companion animal and large animal models offer realistic naturally occuring disease models that more accurately evaluate safety and efficacy of new treatments as they share the heterogeniety of the human population including genetic and physiological variations and the complex interactions of these with the environment.

There are an increasing number of studies emerging from companion animals and large animal species that demonstrate they have much to offer to the human clinic in the quest for the next generation of drug or cell-based therapies and tissue engineering. The use of large animal models will enable greater attention to key questions. These include route of administration as it is not clear as yet which route(s) allow optimal engraftment of injected cells for different diseases. It also needs to be determined whether multiple injections will be more beneficial and if so the question arises whether there is an associated increase in risk of an adverse immune reaction. Cell therapies likely function via a paracrine mechanism and as such alternative approaches such as cell-free extracellular vesicle fractions or soluble factors, need to be explored that may reduce some risks posed by cell administration particularly of allogeneic cells.

For tissue engineered constructs implantation studies using animals with similar size and weight as human patients are crucial to test the implants under relevant biomechanical conditions.

To answer these questions pre-clinical trials with patient cohorts of sufficient size are required which need to be designed robustly to measure appropriate safety and efficacy readouts. Equivalent diseases in animals makes them not only relevant models which offer a more accurate evaluation of safety and efficacy of new treatments, but at the same time are potential beneficiaries of new treatment approaches. Hence, human and veterinary medicine can mutually benefit if one appreciates the similarities.

Author Contributions {#S8}
====================

IR contributed to conceptualization, writing the manuscript, merging the parts contributed by other authors, and revision and editing of the manuscript. PB, AL-C, LM, MP, ES-F, LD, DC, and FS wrote the manuscript. FJ revised and edited the manuscript. JD wrote, revised, and edited the manuscript. LP conceived the idea and wrote, revised, and edited the manuscript. All authors contributed to the article and approved the submitted version.

Conflict of Interest {#conf1}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

We would like to thank Niklas Dresen, Institute of Veterinary Anatomy, University Leipzig as well as John Breteler, Elfriede Cremer, Bernhard Cremer, and Elisabeth Schieder for the provided graphical support and Michaela Hauser for formatting the references. PB acknowledges the funded projects PI15/00563 and PI18/00529 from ISCIII, Spain.

<http://www.isscr.org/docs/guidelines/isscrglclinicaltrans.pdf>

<https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/cellular-gene-therapy-guidances>

<https://ec.europa.eu/health/sites/health/files/scientific_committees/scheer/docs/scheer_o_004.pdf>

<https://omia.org/home/>

<https://goldcopd.org/wp-content/uploads/2016/04/GOLD-2018-WMS.pdf>

[https://www.bhf.org.uk/what-we-do/our-research/heart-statistics/heart-statistics-publications/cardiovascular-disease-statistics-2017](https://wwwbhforguk/research/heart-statistics/heartstatistics-publications/cardiovascular-disease-statistics-2017)

[^1]: Edited by: Dimitrios I. Zeugolis, National University of Ireland Galway, Ireland

[^2]: Reviewed by: Peter Pivonka, Queensland University of Technology, Australia; Janos Kanczler, University of Southampton, United Kingdom

[^3]: This article was submitted to Tissue Engineering and Regenerative Medicine, a section of the journal Frontiers in Bioengineering and Biotechnology
